By Denny Jacob
Corvus Pharmaceuticals shares jumped 29% in premarket trading after new interim data in a study evaluating soquelitinib.
Shares were trading around $4.33. The stock is down 38% on the year.
The clinical-stage biopharmaceutical company said Thursday that new data from a Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis demonstrated a favorable safety and efficacy profile.
Overall, three cohorts showed significant responses in the soquelitinib treatment groups compared to placebo for clinically significant endpoints, said Corvus.
The company said it's on track to initiate a Phase 2 trial before the end of the year.
Soquelitinib is an investigational treatment that selectively inhibits ITK, an enzyme that is expressed mostly in T cells and plays a role in T cell and natural killer cell immune function, according to Corvus.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 09, 2025 08:35 ET (12:35 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.